share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  09/12 08:33

Moomoo AI 已提取核心信息

On September 9, 2024, Cingulate Inc., a biopharmaceutical company, reinstated the annual base salaries of its top executives to pre-reduction levels, following cost containment measures taken in late 2023. The CEO, COO, and CFO saw their salaries return to $503,000, $424,000, and $350,000 respectively. Additionally, on September 12, 2024, Cingulate announced the commencement of its final FDA-required study for CTx-301, a treatment for ADHD. The company expects a data readout from the study by the end of 2024. Cingulate has also successfully raised over $10 million in additional capital since mid-August 2024, with 58% coming from its at-the-market facility, and has been notified by Nasdaq of its compliance with listing requirements. The company continues to operate with a reduced headcount, maintaining approximately 40% fewer employees compared to 2023, resulting in cumulative cash savings of about $1.45 million.
On September 9, 2024, Cingulate Inc., a biopharmaceutical company, reinstated the annual base salaries of its top executives to pre-reduction levels, following cost containment measures taken in late 2023. The CEO, COO, and CFO saw their salaries return to $503,000, $424,000, and $350,000 respectively. Additionally, on September 12, 2024, Cingulate announced the commencement of its final FDA-required study for CTx-301, a treatment for ADHD. The company expects a data readout from the study by the end of 2024. Cingulate has also successfully raised over $10 million in additional capital since mid-August 2024, with 58% coming from its at-the-market facility, and has been notified by Nasdaq of its compliance with listing requirements. The company continues to operate with a reduced headcount, maintaining approximately 40% fewer employees compared to 2023, resulting in cumulative cash savings of about $1.45 million.
2024年9月9日，生科公司Cingulate Inc.恢复了其高管的年薪水平至减少之前的水平，此前公司在2023年底采取了成本控制措施。CEO、COO和CFO的薪酬分别恢复到50.3万美元、42.4万美元和35万美元。此外，2024年9月12日，Cingulate宣布启动其针对CTx-301的最终FDA要求的研究，这是一种治疗ADHD的药物。公司预计将在2024年底前从研究中获得数据。自2024年8月中旬以来，Cingulate还成功筹集了超过1000万美元的资本，其中58%来自其现行市场交易计划，并已收到纳斯达克对其符合上市要求的通知。公司继续以较少的员工数量运营，与2023年相比，员工人数减少了约40%，从而累计节省现金约145万美元。
2024年9月9日，生科公司Cingulate Inc.恢复了其高管的年薪水平至减少之前的水平，此前公司在2023年底采取了成本控制措施。CEO、COO和CFO的薪酬分别恢复到50.3万美元、42.4万美元和35万美元。此外，2024年9月12日，Cingulate宣布启动其针对CTx-301的最终FDA要求的研究，这是一种治疗ADHD的药物。公司预计将在2024年底前从研究中获得数据。自2024年8月中旬以来，Cingulate还成功筹集了超过1000万美元的资本，其中58%来自其现行市场交易计划，并已收到纳斯达克对其符合上市要求的通知。公司继续以较少的员工数量运营，与2023年相比，员工人数减少了约40%，从而累计节省现金约145万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间